Brief: Vincerx Pharma Presents Positive Preliminary Phase 1 Data For Vip236 At The American Association For Cancer Research Annual Meeting 2024
08/04/2024 22:03
April 8 (Reuters) - Vincerx Pharma Inc VINC.O :
* VINCERX PHARMA PRESENTS POSITIVE PRELIMINARY PHASE 1 DATA
FOR
VIP236 AND UPDATES ON PIPELINE PROGRESS AT THE AMERICAN
ASSOCIATION FOR CANCER RESEARCH (AACR) ANNUAL MEETING 2024
Source text for Eikon: ID:nGNX6Dt16M
Further company coverage: VINC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vincerx Pharma
See all newsBrief: Vincerx Pharma Announces Intent To Delist From Nasdaq And Deregister With The SEC
Brief: Vincerx Pharma Announces Termination Of Letter Of Intent And Board Authorization To Pursue Wind-Down Activities
Vincerx Pharma Inc reports results for the quarter ended December 31 - Earnings Summary
Vincerx Pharma Inc expected to post a loss of $3.40 a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Aditxt, Natgas companies, DocuSign